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survival time was observed in VISUM stage 1 patients treated 
with liver resection (n = 52; median survival 37 months) or 
chemoembolization (TACE) and subsequent radiofrequency 
ablation (RFA) (n = 44; median survival 45 months) as com-
pared to patients receiving chemoembolization alone (n = 
107; median survival 13 months) or patients treated by 
tamoxifen only (n = 21; median survival 6 months). Chemo-
embolization alone significantly (p  ^  0.004) improved sur-
vival time in VISUM stage 1–2 patients but not (p = 0.341) in 
VISUM stage 3 patients in comparison to those treated by 
tamoxifen.  Conclusion: Both liver resection or combined 
chemoembolization and RFA improve markedly the survival 
of patients with HCC.  Copyright © 2007 S. Karger AG, Basel 
 Hepatocellular carcinoma (HCC) is one of the most 
frequent malignancies and accounts for as many as 1 mil-
lion  deaths  annually  worldwide   [1–4] .  Most  patients 
with HCC have two diseases – chronic liver disease and 
HCC – and complex interactions between the two have 
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 Abstract 
 Background/Aims: To evaluate the long-term outcome of 
surgical and non-surgical local treatments of patients with 
hepatocellular carcinoma (HCC).  Methods: We stratified a 
cohort of 278 HCC patients using six independent predictors 
of survival according to the Vienna survival model for HCC 
(VISUM-HCC).  Results: Prior to therapy, 224 HCC patients 
presented with VISUM stage 1 (median survival 18 months) 
while 29 patients were classified as VISUM stage 2 (median 
survival 4 months) and 25 patients as VISUM stage 3 (median 
survival 3 months). A highly significant (p  ! 0.001) improved 
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major implications for diagnosis and prognosis as well as 
the management of HCC.
 The clinical course of patients with HCC is deter-
mined by both liver function and the extent of HCC. 
Therefore, after surgical treatment, patients with HCC 
and liver cirrhosis have a less favorable prognosis than 
those without  [5] . Until one decade ago it was generally 
accepted that surgical resection and liver transplantation 
are the only definitive treatments for patients with HCC 
 [6,     7] .     However,     non-surgical     HCC     treatments     such  
as ethanol injection, transarterial chemoembolization 
(TACE) or radiofrequency ablation (RFA) have been suc-
cessfully used as an alternative in patients with HCC 
without surgical options  [8–30] . Only recently, the com-
bination of TACE with subsequent RFA was proposed 
with a potential to eradicate HCCs up to 5 cm in diameter 
completely after one treatment session  [31] .
 Up to now this kind of treatment has not been com-
pared to liver resection (LR) or chemoembolization alone 
in HCC patients. This prompted us to study the long-
term outcome of patients with HCC in respect to these 
different treatments in rather homogenous cohorts of 
HCC patients stratified by a newly constructed Cox 
 proportional model (Vienna survival model for HCC = 
VISUM-HCC)  [32] .
 Patients and Methods 
 Our retrospective study included 278 HCC patients (234 males 
and 44 females) who were diagnosed and staged in the Depart-
ment of Medicine II, Klinikum Grosshadern, University of Mu-
nich, from 1995 to 2006. Patients with early HCC (single nodule 
 ! 5 cm or three nodules  ! 3 cm each) and impaired liver function 
who were considered for orthotopic liver transplantation were not 
evaluated in this investigation.
 To address the problem of selection bias we stratified the co-
hort of 278 HCC patients using six independent predictors of sur-
vival. These included bilirubin ( 1 2 mg/dl), portal vein thrombo-
sis, prothrombin time ( ! 70%),   -fetoprotein (AFP;  1 125 kU/l), 
tumor mass  1 50% and enlarged lymph nodes according to
VISUM-HCC.
 Prior to therapy, 224 HCC patients presented with VISUM 
stage 1 (0–2 points) while 29 patients were classified as VISUM 
stage 2 (3 points) and 25 patients as VISUM stage 3 (4–6 points). 
The kind of treatment and survival time in relation to VISUM 
stage is illustrated in  table 1 .
 We selected for LR mainly those patients who had solitary 
HCC and normal liver function as documented by a Child-Tur-
cotte-Pugh (CTP) score between 5 and 6. Patients who did not fit 
into the surgical criteria either for resection or liver transplanta-
tion were considered for combined treatment with chemoembo-
lization and RFA, chemoembolization alone, or systemic therapy. 
Disease extension was assessed using ultrasound, computed to-
mography (CT) and magnetic resonance tomography (MRI).
 Diagnosis of HCC was confirmed via needle biopsy or via ra-
diological criteria (two coincident imaging techniques) or com-
bined criteria (one imaging technique associated with elevated 
AFP levels) according to Barcelona EASL Conference 2000  [33] . 
Informed consent in writing was obtained from each patient, and 
the study protocol conformed to the ethical guidelines of the 1975 
Declaration of Helsinki as reflected in a priori approval by the 
institutional review committee.
 Treatment Procedures 
 Liver Resection 
 LR was performed according to international surgical stan-
dards for hepatic surgery. Pringles maneuver to reduce blood loss 
was used in most patients. Extension of resection included wedge 
resections, segmental resections, bisegmental resections, as well 
as right and left hepatectomy, respectively.
 Radiofrequency Ablation 
 Patient selection for both RFA and chemoembolization fol-
lowed a consensus decision of an interdisciplinary tumor board 
considering tumor size, number of tumor nodules, localization, 
vascularization, and patients’ general condition. Thus, tumors 
with a size of up to 5 cm in diameter and not more than 5 nodules 
were considered suitable for combined treatment with TACE and 
RFA.
 Since 1999, RFA has usually been performed within 1 week 
after chemoembolization as a minimally invasive, percutaneous 
procedure under conscious analgo-sedation followed by a peri-
interventional, single-shot, broad-spectrum antibiotic.
 All RFA procedures were performed under CT-fluoroscopic 
guidance on a four-slice multidetector scanner (Somatom Sensa-
tion 4, Siemens, Erlangen, Germany) with/without a virtual guid-
ing system (Ultraguide  ). After defining the needle-entry site on 
the skin and giving local anesthesia at the puncture site, the RFA 
electrode (RITA, Starburst XL 5 cm, RITA Medical, Mountain 
View, Calif., USA; LeVeen 4 and 5 cm, Boston Scientific, Munich, 
Germany; Cool-tip cluster, Tyco Healthcare, Neustadt, Germany) 
was inserted and the progress of the electrode to the target lesion 
controlled by CT-fluoroscopy. The electrode size and placement 
was chosen in a way that the target lesion was covered completely 
by the expected ablation volume including a safety margin of 5–10 
Table 1. Kind of treatment and median survival time in 278 pa-
tients with HCC according to VISUM stage
VISUM stage
1 2 3
Liver resection 52 2 0
TACE + RFA 44 2 0
TACE 107 16 12
Tamoxifen 21 9 13
Total 224 29 25
Median survival time, months 18 4 3
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mm to destroy also potential microscopic satellite tumor nests in 
the surrounding lesion  [28, 34] .
 Due to the tumor sizes of up to 5 cm, we applied ablation pro-
tocols resulting in delivered energy of at least 100 kJ per tumor. At 
the end of the procedure, a contrast-enhanced scan was per-
formed with the electrode still in place to document that the tu-
mor was fully covered by the ablation volume and to check for 
potential complications. If an incomplete ablation was suspected 
an immediate subsequent ablation cycle was added. In cases of 
‘critical’ tumor localization, specific precautions were taken such 
as air dissection of adjacent bowel loops or of the gallbladder to 
avoid secondary thermal damage.
 The electrodes were removed under track ablation to avoid 
bleeding from the needle track and potential tumor cell seeding.
 Follow-up studies after TACE and RFA were performed by CT 
or MRI after 6 weeks, then every 3 months in the first year, every 
6 months in the second year, and then every year. Dependent on 
localization and extent of a tumor recurrence, the initial kind of 
treatment was repeated or a chemoembolization alone was per-
formed. A mean number of 1.5 for RFA and 4.2 for TACE was ap-
plied in all of these patients.
 Transarterial Chemoembolization 
 Patients not suitable for surgery or combined treatment with 
TACE and RFA were considered for chemoembolization alone. 
They constitute our study’s largest group which contains patients 
with more than 5 tumor nodules up to 8 cm in diameter. Patients 
with multifocal large ( 1 8 cm tumor nodules) and diffuse growing 
tumors were not included for TACE.
 All TACE procedures were performed under angiographic 
control (Polystar and Axiom Artis, Siemens, Germany) and under 
local anesthesia. After inserting a 4-Fr pigtail catheter into the 
femoral artery via a microincision in the groin, a pan-viscerogra-
phy was performed to detect potential aberrant or additional he-
patic and potentially tumor-feeding arteries. After identifying the 
tumor-feeding arteries, a 4-Fr catheter (e.g. cobra configuration) 
for selective use or a superselective microcatheter, which could be 
placed through the primary 4-Fr catheter, were directed as close 
as possible to the tumor(s)-feeding vessels. The embolizing moi-
ety was prepared by extensive mixing between two syringes (typ-
ically 3–5 ml Lipiodol, microparticles of 150–500   m (e.g. Con-
tour SE  , Boston Scientific, Ratingen, Germany) and farmorubi-
cin (1 mg/kg b.w.). The embolizing agents were then injected 
slowly under fluoroscopic control until stasis within the tumor 
vessels occurred.
 One day after the procedure a baseline CT was performed to 
document the storage of the embolizing agents within the tumor. 
Follow-up studies by triphasic (native and arterial and portal ve-
nous) contrast-enhanced CT were performed 6–12 weeks after 
the initial procedure and then every 3 months. A new TACE was 
performed if there were signs of ‘de-storage’ with revasculariza-
tion of the treated tumor or if new tumors were detected. A mean 
number of 5.0 chemoembolizations was applied in all of these 
patients .
 Systemic Therapy 
 Forty-three HCC patients without options of the above treat-
ments received 20–40 mg tamoxifen as a single dose daily up to 
24 months. Tamoxifen treatment of HCC patients was used until 
2002 in our clinic. Since multiple randomized trials have shown 
that tamoxifen does not prolong survival of patients with HCC 
 [28] , this treatment appeared no longer justified. However, we 
used these patients as a control group reflecting most likely the 
natural course of the disease.
 Follow-Up and Statistical Analysis 
 Survival was set as the primary endpoint of the study. Follow-
up every 3–6 months was computed as starting from the begin-
ning of treatment and was maintained until death or the last vis-
it before March 2006. Patients received clinical examination, 
blood analysis including AFP and imaging techniques (ultra-
sound, spiral CT or MRI, alternatively). Upon detection of failure 
or recurrence, patients were considered for new treatment ses-
sions.
 Probability curves obtained via the Kaplan-Meier method 
were compared using the log-rank test, and for group compari-
sons the    2  and Kruskal-Wallis rank sum test for non-parametric 
values were performed.
 Calculations were done with SPSS package (SPSS Inc., Chica-
go, Ill., USA) and the level of significance was set at p  ! 0.05.
 Results 
 Table 2 depicts the characteristics of the four sub-
groups of the 224 VISUM stage 1 HCC patients. No sig-
nificant difference between the four groups was obtained 
concerning VISUM score, AFP, presence of portal vein 
thrombosis or enlarged lymph nodes. However, prior to 
therapy, bilirubin levels were significantly lower (p  ! 
0.001) and prothrombin times (%) were significantly 
higher (p  ! 0.001) in surgical patients compared to pa-
tients treated with TACE and RFA. In contrast, patients 
selected for combined treatment with chemoemboliza-
tion and RFA had a significantly lower tumor size than 
surgical patients (p  ! 0.001) or patients treated with che-
moembolization (p  ! 0.001) or tamoxifen alone (p  ! 
0.001). Furthermore,  table 2 illustrates survival time (me-
dian and range) in the 224 patients with HCC (VISUM 
stage 1) and local treatment or systemic therapy. Statisti-
cal analysis showed a longer survival time in the sub-
group of patients treated with LR or chemoembolization 
and RFA compared to patients treated with chemoembo-
lization alone (p  ! 0.001) or of all groups compared to 
systemic therapy (p  ! 0.003). Interestingly, median sur-
vival was similar (37 vs. 45 months) in HCC patients 
treated by LR or the combination of chemoembolization 
and RFA.
 Kaplan-Meier plots of the four groups of HCC patients 
(VISUM stage 1) are illustrated in  figure 1 and again 
show a marked survival benefit of HCC patients treated 
by LR or chemoembolization combined with RFA as 
compared to patients treated with chemoembolization or 
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tamoxifen alone.  Table 3 illustrates characteristics and 
survival time of 50 VISUM stage 2–3 HCC patients.
 Comparing 28 patients after chemoembolization to 22 
patients treated by tamoxifen alone, no significant differ-
ence between the two treatment groups was obtained in 
regard to bilirubin, prothrombin time and AFP. However, 
patients treated with tamoxifen showed a higher presence 
of portal vein thrombosis and tumor size appeared to be 
larger compared to those who received chemoemboliza-
tion. Similar as found in VISUM stage 1 patients, che-
moembolization improved the survival (p = 0.022) in
VISUM stage 2–3 patients in comparison to those treated 
with tamoxifen alone. However, this overall difference 
mainly reflected the efficiency of therapy on survival af-
ter chemoembolization in VISUM stage 2 patients ( fig. 2 a) 
while chemoembolization did not significantly improve 
survival in VISUM stage 3 patients when compared to 
treatment with tamoxifen ( fig. 2 b).
 Discussion 
 The management of HCC has improved in recent 
years. However, all kinds of HCC treatment have only a 
limited impact on outcome since most patients with HCC 
suffer from two diseases – chronic liver disease, usually 
at the stage of cirrhosis, and HCC  [35] . Thus, besides the 
extent of the HCC, the grade of liver dysfunction affects 
Variables Liver resection
(n = 52)
TACE + RFA
(n = 44)
TACE
(n = 107)
Tamoxifen
(n = 21)
Age 61.988.9 65.388.3 64.6810.0 65.2811.4
Males/females 42/10 37/7 89/18 18/3
Etiology
HCV 14 11 22 7
HBV 6 5 8 5
Alcohol 11 11 28 5
Other 21 16 41 4
Mixed 0 1 8 0
VISUM score
0 18 18 21 4
1 18 16 39 6
2 16 10 47 11
Bilirubin, mg/dl 1.080.6 1.781.1 1.581.1 1.882.3
Bilirubin, mg/dl
≤2 49 34 88 18
>2 3 10 19 3
Prothrombin time, % 81.4813.5 74.5810.0 76.6813.9 76.9812.8
Prothrombin time, %
>70 46 29 78 16
≤70 6 15 29 5
AFP, kU/l
≤125 36 37 78 14
>125 16 7 29 7
Portal vein thrombosis
Yes 2 1 6 2
No 50 43 101 19
Enlarged lymph nodes
Yes 9 4 16 1
No 43 40 91 20
Tumor size, %
≤50 37 44 73 11
>50 15 0 34 10
Survival time
Months 37 45 13 6
Median/range <1–96 2–77 2–63 <1–31
Table 2. Characteristics of 224 patients 
with HCC (VISUM stage 1) prior to local 
treatment or systemic therapy
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the prognosis of HCC patients. Therefore, most prognos-
tic scores include parameters of liver function.
 An independent evaluation of prognostic scores in a 
Central European cohort of 120 patients with HCC has 
been presented recently by Rabe et al.  [36] . CTP score, 
Okuda score, VISUM-HCC score, Chevret score, Barce-
lona clinic liver cancer classification (BCLC), and cancer 
of the liver Italian programme score (CLIP) were calcu-
lated. Receiver-operating characteristics analysis was 
performed using 6 months of survival as outcome mea-
sure. When the ability to detect a survival of more than 6 
months was tested, all scores performed similarly to the 
Okuda score. Kaplan-Meier analysis of patient survival 
according to VISUM-HCC revealed for stage 1 a cumula-
tive survival between CTP A and B patients, Okuda I–II 
patients, Chevret A–B patients, CLIP 1–2 patients and 
BCLC A–C patients. For VISUM-HCC stage 2–3 patients, 
a cumulative survival comparable to CTP C patients, 
Okuda III patients, BCLC D patients, Chevret C patients 
and CLIP 5– 1 5 patients had been determined. In the 
study of Rabe et al.  [36] the VISUM-HCC appeared most 
suitable in differentiating a group of HCC patients
(VISUM stage 1) with at least moderate survival time 
(median 12 months) from HCC patients with an unfavor-
able prognosis (VISUM stage 2–3) and a short median 
survival of 2–3 months  [36] .
 Therefore, in our retrospective study we used the new 
VISUM-HCC survival model  [32] to select rather homog-
enous cohorts of patients with at least moderate progno-
sis (VISUM stage 1) or dismal prognosis (VISUM stage 
2-3), who had received local treatment of their HCCs by 
LR, combined treatment with chemoembolization and 
RFA, chemoembolization alone or a systemic therapy 
with tamoxifen.
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 Fig. 1. Survival rates determined by Kaplan-Meier of HCC pa-
tients (VISUM stage 1) treated by liver resection (LR) (n = 52), 
combined TACE and RFA (n = 44), TACE alone (n = 107) or 
tamoxifen (n = 21). Statistical evaluation by log-rank test showed 
an improved survival of patients treated by LR compared to TACE 
(p  ! 0.001) and tamoxifen (p  ! 0.001); of patients treated by TACE 
and RFA compared to TACE alone (p  ! 0.001) or tamoxifen (p  ! 
0.001), and of patients treated by TACE alone to tamoxifen (p  ! 
0.003). 
Table 3. Characteristics of 50 patients with HCC (VISUM stage 
2–3) prior to chemoembolization or systemic therapy
Variables TACE (n = 28) Tamoxifen (n = 22)
Age 58.989.4 62.589.3
Males/females 25/3 19/3
Etiology
HCV 5 5
HBV 3 3
Alcohol 8 10
Other 10 4
Mixed 2 0
VISUM score
3 16 9
4 10 9
5 2 3
6 0 1
Bilirubin, mg/dl 3.081.9 7.188.5
Bilirubin, mg/dl
≤2 7 5
>2 21 17
Prothrombin time, % 65.0812.6 67.389.1
Prothrombin time, %
>70 7 7
≤70 21 15
AFP, kU/l
≤125 7 4
>125 21 18
Portal vein thrombosis
Yes 4 11
No 24 11
Enlarged lymph nodes
Yes 12 3
No 16 19
Tumor size, %
≤50 9 2
>50 19 20
Survival time
Months 5.9 2.0
Median/range <1–26 <1–55
 TACE Combined with RFA Improve 
Survival in HCC Patients 
Digestion 2007;75:104–112 109
 Surgical therapeutic options for patients with HCC are 
largely determined by the underlying severity of liver dis-
ease and the extent of the HCC. Liver transplantation is 
the only treatment with the potential to cure both liver 
cirrhosis and HCC. However, due to a worldwide short-
age of donor organs, this undoubtedly most favorable 
treatment is not available for all suitable candidates with 
HCC  [2, 37] . Therefore, local surgical or non-surgical 
treatments of patients with HCC are of increasing impor-
tance. Furthermore, due to improvements of surveillance 
programs of patients with liver cirrhosis and thus at risk 
for HCC, the number of patients available for local treat-
ment of their HCCs will increase in the future  [38] . How-
ever, as in our study,  1 90% of patients with HCC in Eu-
rope and other Western countries have underlying liver 
cirrhosis and are therefore prone to postoperative com-
plications after LR. Even in patients with favorable CTP 
scores (5–6), peri- and postoperative mortality cannot be 
neglected and has led to the recommendation to select for 
resection only those subjects who had solitary HCC, CTP 
scores from 5 to 6 and absence of significant portal hy-
pertension  [39] .
 In our study, LR was performed mainly in patients 
with CTP scores from 5 to 6 (CTP class A) and only ex-
ceptionally also in patients with more impaired liver 
function (CTP class B). In recent years a more strict selec-
tion was applied which excluded patients with significant 
portal hypertension for LR of their HCCs. The outcome 
of our HCC patients treated by LR is comparable to other 
studies  [7, 40–42] . However, when LR is limited to pa-
tients with CTP class A and without significant portal 
hypertension, actuarial survival rates increase up to 74% 
at 5 years  [43] .
 Interestingly, non-surgical patients with HCCs
(VISUM stage 1) treated by the combined application of 
chemoembolization and RFA demonstrated significantly 
better results with regard to survival compared to the 
groups of patients treated with chemoembolization alone 
or systemic therapy with tamoxifen. The combined treat-
ment leads to a definitive necrosis of tumors up to 5 cm 
in diameter in many cases after one single treatment  [31] . 
In comparison to LR, we and others have observed fewer 
side effects and no procedure-related mortality  [44] .
 As has been shown recently, the initial response to per-
cutaneous ablation predicts survival in patients with 
HCC  [45] . Using RFA alone, the initial complete response 
to percutaneous ablation is associated with an improved 
survival in both CTP class A and B patients with non-
surgical HCC. It was concluded that initial tumor necro-
sis should be considered a relevant therapeutic target ir-
respective of tumor size and liver function  [45] .
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 Fig. 2. Survival rates determined by Kaplan-Meier of HCC patients (VISUM stage 2–3) treated by TACE alone 
(n = 28) or tamoxifen (n = 22). Statistical evaluation by log-rank test showed an improved survival of patients 
treated by TACE compared to those treated by tamoxifen in VISUM stage 2 patients (p = 0.004) ( a ) but not in 
VISUM stage 3 patients (p = 0.341) ( b ). 
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 The success of chemoembolization relies on the fact 
that HCC derives its blood supply predominantly from 
the hepatic artery, whereas the surrounding liver receives 
both portal and arterial blood  [16, 17, 46] . However, che-
moembolization is generally considered as palliative 
treatment because it does not achieve a complete necrosis 
of the tumor. This drawback is overcome by combining 
chemoembolization and RFA. The reduced blood flow to 
the tumor by chemoembolization is advantageous since 
it counteracts the rapid transmission of heat supplied by 
the RFA. This is the major reason why the combination 
of chemoembolization and RFA might be superior to 
treatment with RFA alone in HCC patients, although a 
comparative study has not yet been performed. Still, RFA 
is somewhat limited by tumor size and proximity of the 
lesions to larger vascular structures leading to unwanted 
regional cooling effects at the tumor.
 Our patients treated with chemoembolization alone 
showed a less favorable prognosis in the long term. As il-
lustrated in  figure 1 , within the first year their survival is 
not different from patients after LR. However, after an 
extended follow-up period, only a few patients survived 
3 years. Although all patients belong to a group of pa-
tients with an at least moderate prognosis (VISUM stage 
1), it is evident from  table 2 that HCC patients treated 
with chemoembolization alone had more extended HCCs 
than patients treated with chemoembolization and RFA, 
and a more impaired liver function than patients treated 
by LR. The different liver function might contribute to 
the median survival difference (24 months) between
VISUM stage 1 HCC patients treated by LR compared to 
VISUM stage 1 HCC patients treated by chemoemboliza-
tion alone. Furthermore, it cannot be neglected that the 
median survival difference (32 months) between patients 
treated with TACE and RFA vs. TACE alone might par-
tially reflect the more extended and/or multifocal presen-
tation of HCCs in the latter group. Indeed, due to our 
selection criteria for the different treatments, TACE and 
RFA were restricted to HCC patients with a tumor size of 
up to 5 cm in diameter and not more than 5 nodules, 
while HCC patients with  1 5 nodules up to 8 cm in diam-
eter were accepted for treatment with TACE alone. How-
ever, it is very unlikely that a median survival difference 
of 32 months (45 vs. 13 months) between both groups of 
patients is solely due to a different extension of the HCC. 
In the analysis of Rabe et al.  [36] , tumor extension as de-
termined by the number of nodules, largest nodule, lymph 
node metastases, involvement of both liver lobes and in-
volvement of  1 50% of the liver was not different between 
HCC patients surviving  ! 6 and  1 6 months.
 Finally, our group of patients with VISUM stage 1 
treated by tamoxifen alone shows the least favorable prog-
nosis in the long term and no surviving patients after 3 
years. The statistical evaluation of survival times revealed 
that besides LR and the combined treatment with TACE 
and RFA, TACE alone improved the survival of our HCC 
patients in VISUM stage 1 compared to patients treated 
by tamoxifen only. The extent of the median survival 
benefit of 7 months is in accordance with a recent system-
atic review of randomized trials for unresectable HCC, 
which showed a significant benefit of chemoemboliza-
tion in comparison to tamoxifen alone  [28] . Similarly, 
chemoembolization in HCC patients of VISUM stage 2 is 
superior to tamoxifen alone and seems therefore justi-
fied, while chemoembolization in HCC patients of
VISUM stage 3 did not significantly improve survival 
time in comparison to systemic therapy by tamoxifen and 
thus should be avoided.
 In conclusion, our data show that patients with HCC 
and an at least moderate prognosis according to the
VISUM-HCC have a more favorable long-term survival 
if LR or a combined treatment with chemoembolization 
plus RFA is possible. These results underscore the impor-
tance of surveillance programs for the early detection of 
HCCs in patients with chronic liver disease. Interesting-
ly, the outcome of the non-surgical patients treated by 
combined TACE and RFA was comparable to the group 
of HCC patients treated with LR.
 If these results hold true in a larger cohort of patients, 
combined treatment with TACE and RFA may also be an 
alternative to surgery in some patients with small HCCs 
and preserved liver function.
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